Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK plc reported small share purchases by several senior executives under its Share Reward Plan. On 2025-09-09, CEO Emma Walmsley acquired 18 ordinary shares, split between partnership and matching shares, at £14.8574 per share on the London Stock Exchange. CFO Julie Brown acquired 16 ordinary shares on the same terms and date.
Additional participants included senior leaders such as the Group General Counsel, heads of corporate development, global supply chain, global affairs, ViiV Healthcare and global health, global communications, and the company secretary. Each of these executives acquired between 16 and 18 ordinary shares, also at £14.8574 per share through the plan.
GSK plc announced that, acting through Merrill Lynch International, it purchased 207,767 ordinary shares on 09 September 2025 at an average price of 1,483.93p per share as part of its ongoing buyback programme.
The purchased shares will be held as Treasury shares. Since the non-discretionary broker agreement dated 4 June 2025, the Company has acquired 28,019,060 ordinary shares in total. After this transaction GSK will hold 246,153,443 ordinary shares in treasury and will have 4,069,248,284 ordinary shares in issue (excluding Treasury shares). The total number of voting rights is 4,069,248,284 and the percentage of voting rights attributable to treasury shares is 6.05%.
GSK plc reported an on-market purchase of 219,116 ordinary shares on 08 September 2025, executed by Merrill Lynch International under the non-discretionary buyback agreement announced 4 June 2025. The shares were bought at prices ranging around 1,460.93p to 1,485.50p per share and will be held as Treasury shares. Since 4 June 2025 the Company has purchased 27,811,293 ordinary shares under the same programme. After this transaction GSK will hold 245,945,676 ordinary shares in treasury and have 4,069,456,051 ordinary shares in issue (excluding Treasury shares), giving a total number of voting rights of 4,069,456,051. The Company states Treasury shares represent 6.04% of voting rights following the purchase.
GSK plc reported a transaction in own shares under its existing buyback programme. On 05 September 2025 the company, acting through Merrill Lynch International, purchased 276,710 ordinary shares at an average price of 1,472.87 pence per share. Since entering the non-discretionary agreement on 4 June 2025 the Company has purchased 27,592,177 ordinary shares. After this purchase GSK will hold 245,726,560 ordinary shares in treasury and will have 4,069,675,167 ordinary shares in issue excluding treasury shares, giving a total number of voting rights of 4,069,675,167. The Company reports that ordinary shares held in treasury represent 6.04% of voting rights following the purchase. Detailed individual trade prices and transaction references for the purchases on 05 September 2025 are provided in the filing.
GSK plc reports that on 04 September 2025 it repurchased 284,800 ordinary shares at an average price of 1,464.66p per share through Merrill Lynch International under its announced buyback programme. The purchased shares will be held as Treasury shares. Since the programme began on 4 June 2025, GSK has bought 27,315,467 ordinary shares. After this transaction the company holds 245,449,850 shares in treasury and has 4,069,946,246 ordinary shares in issue (excluding treasury), giving total voting rights of 4,069,946,246 and treasury-held voting rights of 6.03%.
GSK plc filed a Form 6-K reporting a transaction notification dated September 04, 2025. The filing identifies the security by ISIN GB00BN7SWP63 and discloses an aggregated volume of 10,050 shares. The document provides the transaction date and quantity but does not state the transaction price, the identity of the reporting person or counterparty, or aggregated price information.
GSK plc reports a routine purchase of its ordinary shares under an existing buyback programme. On 03 September 2025 the Company, through Merrill Lynch International, purchased 232,912 ordinary shares at prices in the range shown in the schedule and will hold the purchased shares as Treasury shares. Since the non-discretionary agreement dated 4 June 2025, the Company has purchased 27,030,667 ordinary shares. After this trade the Company holds 245,165,050 ordinary shares in treasury and has 4,070,231,046 ordinary shares in issue (excluding treasury); total voting rights are 4,070,231,046 and the percentage of voting rights attributable to treasury shares is 6.02%.
GSK plc announced that, acting through Merrill Lynch International, it purchased 296,202 ordinary shares of 31 3/4 pence each on 02 September 2025 at prices between 1,440.50p and 1,469.00p. The purchased shares will be held as treasury stock and form part of the company’s existing buyback programme under a non-discretionary agreement with the broker signed 4 June 2025. Since 4 June 2025 the company has bought 26,797,755 ordinary shares. After this transaction GSK will hold 244,932,138 shares in treasury, have 4,070,463,958 ordinary shares in issue excluding treasury shares, and a total number of voting rights of 4,070,463,958. The company reports that treasury shares represent 6.02% of voting rights following the purchase.
GSK plc reported a transaction in own shares under its announced buyback programme. Acting through Merrill Lynch International on 01 September 2025 the Company purchased 227,465 ordinary shares at prices between 1,442.00p and 1,468.50p per share; the aggregated lowest and highest reported prices on the day were 1,451.50p and 1,468.50p respectively. The purchased shares will be held as treasury shares and form part of the non-discretionary agreement with the Broker entered into on 4 June 2025. Since 4 June 2025 the Company has purchased 26,501,553 ordinary shares. Following this purchase the Company will hold 244,635,936 shares in treasury, have 4,070,760,160 ordinary shares in issue (excluding treasury) and treasury shares represent 6.01% of voting rights.
GSK plc reports its issued share capital and total voting rights as of 31 August 2025. The company had 4,315,396,096 Ordinary Shares of 31 pence each, of which 244,408,471 were held in Treasury, leaving a total of 4,070,987,625 voting rights. Shareholders may use this figure as the denominator to determine whether they must notify changes in their holdings under the FCA Disclosure Guidance and Transparency Rules.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
